EGFR and lung adenocarcinoma: This study therefore aimed to investigate the clinical efficacy and prognosis traits of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy for advanced lung adenocarcinoma with EGFR 19Del, L858R mutation.